CJC 1295 No Dac + Ipamorelin Blend

Prime Peptide's CJC-1295 No DAC + Ipamorelin research blend

CJC-1295 No DAC + Ipamorelin is a dual-peptide laboratory research blend designed for controlled studies involving growth hormone signalling, receptor activity and peptide interaction pathways. By combining two widely studied compounds in a single research material, this blend allows researchers to explore their complementary mechanisms within one consistent preparation.

CJC-1295 No DAC, also known as Modified GRF 1-29, is a short-acting growth hormone-releasing hormone analogue. Ipamorelin is a selective growth hormone secretagogue commonly studied for its interaction with the ghrelin receptor. Together, these peptides are frequently investigated in laboratory models examining pulsatile growth hormone release, receptor selectivity and coordinated peptide signalling.

What is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC and Ipamorelin act through different but related signalling pathways. CJC-1295 No DAC is studied for its interaction with growth hormone-releasing hormone receptors, while Ipamorelin is researched for its activity at growth hormone secretagogue receptors.

Because the two compounds operate through distinct receptor systems, the combination is commonly used in research focused on synergistic peptide activity, endocrine signalling patterns and coordinated growth hormone pathway stimulation.

About CJC-1295 No DAC

CJC-1295 No DAC is the short-acting form of Modified GRF 1-29. Unlike DAC-modified versions, it does not contain the Drug Affinity Complex component that extends circulation time. This makes CJC-1295 No DAC particularly relevant for research examining shorter-duration signalling and naturally patterned peptide activity.

Laboratory investigations involving CJC-1295 No DAC often focus on growth hormone-releasing hormone receptor activation, pituitary signalling and time-dependent hormone release models.

About Ipamorelin

Ipamorelin is a synthetic pentapeptide classified as a selective growth hormone secretagogue. It is primarily studied for its interaction with the ghrelin receptor, also known as the growth hormone secretagogue receptor.

Researchers frequently evaluate Ipamorelin because of its receptor selectivity and its role in laboratory models involving peptide-induced growth hormone signalling. Its selective profile makes it useful in comparative studies involving other growth hormone secretagogues.

Why researchers study the blend

The CJC-1295 No DAC + Ipamorelin blend is commonly selected for research where two complementary peptide pathways need to be evaluated together. Combining a growth hormone-releasing hormone analogue with a growth hormone secretagogue allows researchers to investigate how separate receptor systems may interact within the same experimental model.

• Dual-pathway research: Supports investigation of both GHRH receptor and ghrelin receptor signalling.
• Synergistic models: Useful for studies examining coordinated peptide activity.
• Short-acting research profile: CJC-1295 No DAC is suitable for studies focused on pulsatile or time-dependent signalling.
• Selective receptor activity: Ipamorelin is frequently researched for its relatively selective secretagogue profile.
• Consistent blend format: Both peptides are supplied together for convenient laboratory preparation and comparison.

Research applications

CJC-1295 No DAC + Ipamorelin may be used in controlled laboratory research involving:

• growth hormone signalling pathways
• growth hormone-releasing hormone receptor activity
• ghrelin receptor interaction
• pulsatile endocrine signalling models
• peptide synergy and receptor cross-talk
• cellular signalling associated with growth hormone pathways
• comparative analysis of peptide secretagogues
• time-dependent peptide response studies

Product information

• Product: CJC-1295 No DAC + Ipamorelin Blend
• Compound type: Dual-peptide research material
• Form: Lyophilised powder
• Presentation: Sealed laboratory vial
• Research category: GHRH analogue and growth hormone secretagogue blend
• Intended use: Laboratory and analytical research

Quality and consistency

Prime Peptide supplies CJC-1295 No DAC + Ipamorelin as a premium laboratory research blend prepared with attention to purity, consistency and handling quality. A reliable blend format helps researchers reduce variation between individual preparations and maintain greater consistency across repeated experiments.

Each vial is intended to support controlled research environments where accurate identification, reliable presentation and consistent material quality are important.

Storage and handling

Store the unopened lyophilised vial in a cool, dry environment away from direct sunlight, heat and moisture. For longer-term laboratory storage, refrigeration may be preferred depending on the research protocol and available stability documentation.

Once prepared for laboratory use, the material should be handled using appropriate sterile research procedures. Avoid repeated temperature fluctuations and unnecessary exposure to light.

Ordering CJC-1295 No DAC + Ipamorelin in India

Prime Peptide provides CJC-1295 No DAC + Ipamorelin research material for laboratories, institutions and qualified researchers across India. Orders are securely packed to help protect vial integrity during transit.

Before placing an order, researchers should confirm the required blend strength, laboratory protocol and storage conditions. Product availability and specifications may vary, so the selected vial details should be reviewed carefully before checkout.

Frequently asked questions

What is the difference between CJC-1295 No DAC and CJC-1295 with DAC?

CJC-1295 No DAC is a shorter-acting GHRH analogue commonly associated with pulsatile research models. CJC-1295 with DAC contains a modification designed to extend its duration of activity.

Why are CJC-1295 No DAC and Ipamorelin combined?

The blend combines two peptides that act through different receptor pathways. CJC-1295 No DAC is studied for GHRH receptor activity, while Ipamorelin is studied for growth hormone secretagogue receptor activity. Researchers may use the combination to examine coordinated or complementary signalling.

Is the product supplied as a lyophilised powder?

Yes. The blend is generally supplied in lyophilised form to support stability during storage and transport.

Is CJC-1295 No DAC + Ipamorelin intended for laboratory research?

Yes. This material is supplied exclusively for controlled laboratory, analytical and scientific research.

Does the blend contain CJC-1295 with DAC?

No. This blend contains CJC-1295 No DAC, also known as Modified GRF 1-29, together with Ipamorelin.

Research use disclaimer

This material is not a medicine, supplement, cosmetic or food product and is intended exclusively for laboratory research. It is not intended for human or veterinary administration, diagnosis or treatment.